Cannabidiol for Inflammatory Bowel Disease

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

There are many anecdotal reports about improvement of Inflammatory bowel diseases (IBD) with cannabis smoking. The most effective anti inflammatory compound known today is cannabidiol. cannabidiol can be extracted from the cannabis plant, it has no central effect and is fat soluble so it can be given as drops in oil. Doses of up to 500mg did not cause any side effects.

The aim of the proposed study is to examine in a double blind placebo controlled fashion the effect of cannabidiol on disease activity in patients with IBD.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Meir Medical Center
• Treatments: Cannabidiol

Criteria

Inclusion Criteria:

1. Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study.

2. Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will be offered the possibility of receiving cannabidiol at a dose of 10 mg in sub lingual drops or drops of olive oil as placebo.

3. Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC.

4. Age above 20.

Exclusion Criteria:

1. Patients with a known mental disorder

2. Patients who are deemed to be at a high risk of abuse or addiction to the study drug.

3. Pregnant women

4. Patients who are sensitive to any of the ingredients of the study medication.

5. Patients who are unable to give informed consent.

6. Patients who may need surgery in the near future.